von Haehling Stephan, Jankowska Ewa A, Ponikowski Piotr, Anker Stefan D
Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany.
Future Cardiol. 2011 Jan;7(1):119-29. doi: 10.2217/fca.10.110.
Chronic heart failure is a substantial public health problem. Anemia is an important comorbidity frequently observed in patients with the disease and, in heart failure, anemia has only recently started to attract systematic epidemiological and therapeutical research endeavor. This article describes the many aspects of anemia in chronic heart failure, starting with the ongoing discussion of how to define anemia, which has important consequences for the estimation of its prevalence and incidence. Further, we discuss prognostic implications of anemia in patients with chronic or acute heart failure, the etiology of anemia in heart failure and treatment possibilities. Such therapeutic avenues embrace intravenous iron preparations and subcutaneous administration of erythropoietin and its derivatives, all of which have been extensively studied over the last several years. Finally, this article describes the potential costs incurred by treating anemic patients with heart failure.
慢性心力衰竭是一个重大的公共卫生问题。贫血是该疾病患者中常见的重要合并症，在心力衰竭中，贫血直到最近才开始吸引系统的流行病学和治疗研究。本文描述了慢性心力衰竭中贫血的诸多方面，首先是关于如何定义贫血的持续讨论，这对其患病率和发病率的估计有重要影响。此外，我们讨论了贫血对慢性或急性心力衰竭患者的预后影响、心力衰竭中贫血的病因以及治疗可能性。这些治疗途径包括静脉注射铁制剂和皮下注射促红细胞生成素及其衍生物，在过去几年中对所有这些都进行了广泛研究。最后，本文描述了治疗心力衰竭贫血患者可能产生的费用。
